Total Clarity Wealth Management Inc. Has $1.13 Million Stock Position in Amgen Inc. $AMGN

Total Clarity Wealth Management Inc. cut its stake in Amgen Inc. (NASDAQ:AMGN) by 62.1% during the 1st quarter, HoldingsChannel.com reports. The fund owned 3,222 shares of the medical research company’s stock after selling 5,269 shares during the period. Total Clarity Wealth Management Inc.’s holdings in Amgen were worth $1,134,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in AMGN. Stonebridge Financial Group LLC MO raised its stake in Amgen by 4.3% during the first quarter. Stonebridge Financial Group LLC MO now owns 1,138 shares of the medical research company’s stock worth $400,000 after buying an additional 47 shares during the last quarter. Sovereign Financial Group Inc. grew its holdings in Amgen by 2.5% during the 1st quarter. Sovereign Financial Group Inc. now owns 1,779 shares of the medical research company’s stock worth $626,000 after acquiring an additional 44 shares during the period. AdvisorNet Financial Inc grew its holdings in Amgen by 16.3% during the 1st quarter. AdvisorNet Financial Inc now owns 6,251 shares of the medical research company’s stock worth $2,200,000 after acquiring an additional 877 shares during the period. Community Bank & Trust Waco Texas raised its position in shares of Amgen by 1.5% in the 1st quarter. Community Bank & Trust Waco Texas now owns 10,280 shares of the medical research company’s stock worth $3,617,000 after acquiring an additional 147 shares in the last quarter. Finally, Anchyra Partners LLC lifted its stake in shares of Amgen by 4.6% in the 1st quarter. Anchyra Partners LLC now owns 2,990 shares of the medical research company’s stock valued at $1,052,000 after purchasing an additional 131 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Piper Sandler reiterated an “overweight” rating on shares of Amgen in a report on Friday, June 12th. Erste Group Bank reaffirmed a “hold” rating on shares of Amgen in a research report on Tuesday, May 5th. The Goldman Sachs Group set a $389.00 target price on shares of Amgen in a research report on Friday, June 5th. Truist Financial raised their price target on shares of Amgen from $325.00 to $327.00 and gave the stock a “hold” rating in a report on Friday, May 1st. Finally, Leerink Partners reissued a “market perform” rating and set a $355.00 price objective on shares of Amgen in a research report on Thursday, March 5th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Amgen has an average rating of “Hold” and a consensus price target of $354.42.

Amgen Stock Performance

Shares of Amgen stock opened at $344.72 on Tuesday. The company has a market cap of $186.05 billion, a PE ratio of 23.99, a price-to-earnings-growth ratio of 3.39 and a beta of 0.42. Amgen Inc. has a 52 week low of $267.83 and a 52 week high of $391.29. The business has a 50 day moving average price of $340.50 and a 200-day moving average price of $345.86. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter last year, the company earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities analysts anticipate that Amgen Inc. will post 22.38 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.85% of the company’s stock.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.